menu
    • menu

    PDF presentation for Aurigene Pharmaceutical Services

    Aurigene Pharma-PSE
    News
    Dr. Reddy's, Aurigene, And Kainomyx Announce Potential Malaria Drug Partnership

    20 Aug 2024

    // PRESS RELEASE

    Aurigene to Provide Cell Therapy Discovery Services

    01 Jul 2024

    // PRESS RELEASE

    Aurigene Opens Biologics Facility For Process, Clinical Manufacturing

    03 Jun 2024

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Aurigene Pharmaceutical Services

    Contact Supplier

    Website

    CPhI Worldwide, Milan

    Booth #7B82

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/mDRRzUFUk0A?si=0f9qDxEXEPjRuPFf

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Aurigene

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Related CompaniesRelated Companies

    About

    Aurigene Pharmaceutical Services is a CRO/CDMO with over two decades of experience. It offers a range of services for new therapeutics, from drug discovery, clinical research and development to manufacturing APIs and formulations at commercial scales. It has development laboratories from discovery to clinical phase 3 and cGMP manufacturing sites in the UK, Mexico, the USA and India. Its technology platforms include cytotoxic APIs, carbohydrates, steroids, PEG derivatives, prostaglandins, peptides and oligonucleotides. Its large molecule discovery services include ADC, MAB, MRNA and CART-T. Aurigene's two R&D centers are USFDA inspected.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aurigene Pharmaceutical Servicesindia-flag Flag
    Country
    Country
    India
    Address
    Address
    39-40 Hosur Road KIADB Industrial Area, Joggers Ln, Phase 2, Electronic City, ...
    Telephone
    Telephone
    +91 7386722272
    Client Email
    Email
    contactapsl@aurigeneservices.com
    Client Website
    Website
    https://www.aurigeneservices.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/aurigenepharmaceuticalservices/
    Twitter
    Twitter
    https://twitter.com/AurigenePharma
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    cphi-worldwide-milan-70313.png

    CPhI Worldwide, Milan

    Booth #7B82

    envelop Contact Supplier

    CPhI Worldwide, Milan

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/aurigene-pharmaceutical-services-party-content-38979.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Analytical Chemistry

    read-more

      https://www.pharmacompass.com/pdf/party/content/aurigene-pharmaceutical-services-party-content-98174.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Toxicology

    read-more

      https://www.pharmacompass.com/pdf/party/content/aurigene-pharmaceutical-services-party-content-58225.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Antibody Drug Conjugate (ADC)

    read-more

      https://www.pharmacompass.com/pdf/party/content/aurigene-pharmaceutical-services-party-content-72281.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Viral Vector

    read-more

      https://www.pharmacompass.com/pdf/party/content/aurigene-pharmaceutical-services-party-content-11091.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Process Development

    read-more

      https://www.pharmacompass.com/pdf/party/content/aurigene-pharmaceutical-services-party-content-4169.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    cGMP Development and Manufacturing Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/aurigene-pharmaceutical-services-party-content-97302.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Discovery, Development and Manufacturing Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/aurigene-pharmaceutical-services-party-content-98887.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Formulation Development Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/aurigene-pharmaceutical-services-party-content-1653372677.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Methoxy Polyethylene Glycol

    read-more

      https://www.pharmacompass.com/pdf/party/content/aurigene-pharmaceutical-services-party-content-1653372585.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Custom Peptide Synthesis

    read-more

      https://www.pharmacompass.com/pdf/party/content/aurigene-pharmaceutical-services-party-content-20994.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    High Potent API (HPAPI) Manufacturing Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/aurigene-pharmaceutical-services-party-content-1653372213.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik.View CDMO Activity Tracker for H1 2024 (Free Excel Available) Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services.View CDMO Activity Tracker for H1 2024 (Free Excel Available)  Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs.View CDMO Activity Tracker for H1 2024 (Free Excel Available)  EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal.View CDMO Activity Tracker for H1 2024 (Free Excel Available)  Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2371

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities

    #PharmaFlow by PHARMACOMPASS
    08 Aug 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Dr. Reddy's, Aurigene, And Kainomyx Announce Potential Malaria Drug Partnership
    Dr. Reddy's, Aurigene, And Kainomyx Announce Potential Malaria Drug Partnership

    20 Aug 2024

    // PRESS RELEASE

    https://www.aurigeneservices.com/sites/default/files/2024-08/Media%20note-%20DRL-APSL%20partnership%20with%20Kainomyx.pdf

    PRESS RELEASE
    20 Aug 2024
    Share Share
    Aurigene to Provide Cell Therapy Discovery Services